## **Vinda International Holdings Limited**



(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3331)

## 2016 Interim Results Investor Presentation





# **Key Accomplishments**

# **Key Accomplishments in 1H2016**



### Ambition

To become a leading hygiene company in Asia



1.Excluding acquisition and exchange rate effects 2.Excluding acquisition effect





(НК\$М)	1H2016	1H2015	Change
Revenue*	5,666	4,743	+19.5%
Gross profit	1,772	1,497	+18.4%
EBITDA	831	702	+18.3%
Operating profit	515	468	+9.9%
Net profit	321	331	-2.9%
Basic earnings per share (HK cents)	30.6	33.1	
Proposed interim dividend per share (HK cents)	5.0	5.0	

\* Organic revenue growth: 14.5%<sup>1</sup>

<sup>1</sup>Excluding acquisition and exchange rate effects





# **Enlarged Personal Care Portfolio**



	1H2015	2H2015	1H2016	1H2016	
Revenue				Organic revenue g	rowth <sup>3</sup>
Tissue	4,583 (97%)	4,774 (96%)	<b>4,923</b> <i>(87%)</i>	Tissue	14%
Personal Care	160 (3%)	178 (4%)	<b>743</b> (13%) <sup>1</sup>	Personal Care	22%
Total	4,743 (100%)	4,952 (100%)	5,666 (100%)	Total	14.5%
Croco morgin					
Gross margin Tissue	31.7%	29.6%	31.5%		
Personal Care	26.2%	26.5%	29.7%		
Total	31.6%	29.5%	31.3%		
Segment results <sup>2</sup> margin					
Tissue	12.3%	9.4%	11.1%		
Personal Care	(28.2%)	(29.1%)	5.4%		

<sup>1</sup> Personal care accounted for 4% and 21% of total revenue in 1Q16 and 2Q16 respectively

<sup>2</sup> Segment results: segment profit before amortisation of trademarks, licenses & contractual customer relationship

<sup>3</sup> Excluding acquisition and exchange rate effects





Items Affecting Comparability (HK\$M)	1H2016	1H2015
Operating items:		
Foreign exchange gain/ (loss)	(14)	(32)
<ul> <li>Amortisation of the acquired intangible assets related to the acquisition on 1 Apr 2016 (non-cash item)<sup>2</sup></li> </ul>	(14)	-
Transaction cost related to acquisition	(3)	-
Financing items:		
Foreign exchange gain/ (loss)	(1)	2
Fair value downward adjustment on convertible note (non-cash item)	(18)	-

<sup>1</sup> Excluding items affecting comparability

<sup>2</sup> It will only be presented as an item affecting comparability where it was not included in comparative prior year period





#### Effective Tax Rate



- Selling & marketing expenses ratio
  - Increase in SG&A ratio
    - Due to the amortisation of the acquired intangible assets related to the acquisition on 1 Apr 2016 (non-cash item)
    - Due to the continuing commitment to brand building & promotional activities for Vinda brand, new brands & personal care business

- Increase in effective tax rate, mainly due to:
  - Non-tax deductible items including fair value downward adjustment on convertible note

## **Key Ratios**

(HK\$M)	2016	2015	2015
Debtors turnover days	44	43	45
Creditors turnover days	66	79	71
Finished turnover days	45	43	40
Working capital to sales ratio	14%	14%	16%
(HK\$M)	As at 30 Jun 2016	As at 31 Dec 2015	As at 30 Jun 2015
Cash and cash equivalents <sup>1</sup>	632	393	514
Total borrowings <sup>2</sup>	5,666	4,739	4,528
Borrowings in CNY (%)	61%	42%	10%
Net debt	5,035	4,345	4,014
Net gearing ratio <sup>3</sup> (%)	74%	88%	76%
Interest coverage <sup>4</sup> (times)	5.8	6.2	7.4

As at 30 Jun

#### As at 30 June 2016:

- Total outstanding loans from SCA: HK\$1.8 B
- Total unutilized credit facilities (incl. unutilized loan from SCA): HK\$5.7 B

1. Incl. restricted bank deposit. 2. Total borrowings (incl. SCA shareholder loan)

As at 31 Dec

As at 30 Jun

#### HK\$390M net proceeds from share placement in May 2016

Lower gearing level

Reduced FX exposure by increasing proportion of CNY loans



<sup>3.</sup> Total borrowing less bank balances and cash and restricted deposits / total shareholders' equity. 4. Underlying EBIT/interest (times), excluding interest capitalisation factor.

## **Rapid Growth in E-commerce**



#### **Revenue**<sup>1</sup> (by sales channels)



- Traditional channels (i.e. Distributiors)
- B2B (i.e. Corporate clients)
- Modern channels (i.e. Hypermarkets, Supermarkets)
- E-Commerce

<sup>1</sup> Excluding the acquired sales in 2016



## **Enhanced Tissue Mix**



### Tissue Revenue<sup>1</sup> (by categories)



<sup>1</sup>Excluding the acquired sales in 2016

<sup>2</sup>Excluding acquisition & exchange rate effects

# **Future Outlook**

## **Mid-Long Run Growth Catalysts**





## **Strong Market Positions**





- According to SCA's internal estimates
   Kantar Worldpanel Malaysia, MAT 16 May 2016
- Nielsen volume for 12 months ending 31 May 2016

## **Strong Supply Chain Support**



Annual Designed Production Capacity (tons)			
Production sites	1H2016	Add in 2H2016	2016 end
Xinhui, Sanjiang	380,000	60,000	440,000
Hubei	180,000		180,000
Zhejiang	150,000		150,000
Shandong	80,000	30,000	110,000
Liaoning	55,000		55,000
Sichuan	75,000		75,000
Beijing	30,000		30,000
Total	950,000	90,000	1,040,000

Personal Care

- 2 production plants in Malaysia and 1 in Taiwan China
- Incontinence care production facilities in **Zhejiang**
- · Baby care production facilities in Hubei

#### SCA support

• Ongoing cost-free support from SCA on R&D, branding etc.

#### 17

## **Our Priorities**

#### Ambition

#### To become a leading hygiene company in Asia



# Drive Tissue business in China

- Drive Tissue sales in China with innovativedriven product R&D & marketing campaigns
- Increase contribution from
   Tempo in high-end market

## Broaden the Personal Care presence in China

- Become the leader in Incontinence with TENA & Dr. P
- Establish feminine as a future profit contributor
- Selective presence in competitive baby market





Drive Personal Care growth in Asia & roll out tissue

- Strengthen Personal Care market positions where we have presence
- Roll out tissue to Asia by leverage the strong route to market



## **Core Principles**





## **Sustainability**

- Consumer-focused
- Technology-focused
- Leverage global technological platform

### Integrity



- 100% certified pulp
- Reduce energy consumption
- Reduce water usage



#### Innovation

- Good corporate
   governance
- Code of conduct
- Compliance



# Q&A

## **Disclaimer**



Information contained in our presentation is intended solely for your personal reference and is strictly confidential. Such information is subject to change without notice, its accuracy is not guaranteed and it may not contain all material information concerning the company and/or its business. We make no representation or warranty, express or implied, regarding, and assumes no responsibility or liability for, the fairness, accuracy, correctness or completeness of, or any errors or omissions in, any information or opinions contained herein.

In addition, the information contains projections and forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These views are based on current assumptions which are subject to various risks and which may change over time. No assurance can be given that future events will occur, that projections will be achieved, or that the company's assumptions are correct. Actual results may differ materially from those projected. It is not the intention to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of the Company's financial or trading position or prospects.

This presentation does not constitute an offer or invitation to purchase or subscribe for any shares and no part of it shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto.



# **Thank You**



